VA-MENGOC-BC® 疫苗诱导的交叉保护作用。
Cross-protection induced by VA-MENGOC-BC® vaccine.
机构信息
a Department of Immunology , Institute of Basic and Preclinical Sciences, University of Medical Sciences, Senior Researcher at the Finlay Institute of Vaccines , Havana , Cuba.
出版信息
Hum Vaccin Immunother. 2018 May 4;14(5):1064-1068. doi: 10.1080/21645515.2018.1438028. Epub 2018 Feb 26.
Abstract
I would like to comment on the article "Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief", DOI: 10.1080/21645515.2017.1381810. The author states that meningococcal group B OMVs vaccines -such as VA-MENGOC-BC®- may induce moderate protection against Neisseria gonorrhoeae. I agree. However, the author states that "there was no evidence of effectiveness in the younger children." The effectiveness of VA-MENGOC-BC® in heterologous contexts has been higher than 80% in individuals older than 4 years old, but the effectiveness in younger children should not be undervalued; it has usually been higher than 60%, and results markedly higher when evaluated based on mortality rates. There is strong evidence that VA-MENGOC-BC® may induce cross-protection against heterologous N. meningitidis strains and N. gonorrhoeae.
摘要
我想对文章“评论：脑膜炎奈瑟菌 B 型 OMV 疫苗的影响，超出其短暂性”，DOI：10.1080/21645515.2017.1381810. 进行评论。作者指出，脑膜炎奈瑟菌 B 型 OMV 疫苗 - 如 VA-MENGOC-BC® - 可能对淋病奈瑟菌产生适度的保护作用。我同意这一观点。然而，作者指出，“在年幼的儿童中没有证据表明其有效性。”VA-MENGOC-BC®在异源环境中的有效性在 4 岁以上的个体中高于 80%，但不应低估其在年幼儿童中的有效性；其有效性通常高于 60%，当根据死亡率进行评估时，结果明显更高。有强有力的证据表明，VA-MENGOC-BC®可能诱导针对异源脑膜炎奈瑟菌菌株和淋病奈瑟菌的交叉保护作用。
相似文献
1
Cross-protection induced by VA-MENGOC-BC® vaccine.
Hum Vaccin Immunother. 2018 May 4;14(5):1064-1068. doi: 10.1080/21645515.2018.1438028. Epub 2018 Feb 26.
2
Impact of meningococcal group B OMV vaccines, beyond their brief.
Hum Vaccin Immunother. 2018 May 4;14(5):1058-1063. doi: 10.1080/21645515.2017.1381810. Epub 2017 Nov 17.
3
Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential.
MEDICC Rev. 2019 Oct;21(4):19-27. doi: 10.37757/MR2019.V21.N4.4.
4
VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.
Pediatr Infect Dis J. 2021 Apr 1;40(4):375-381. doi: 10.1097/INF.0000000000003047.
5
A meningococcal B vaccine induces cross-protection against gonorrhea.
Clin Exp Vaccine Res. 2019 Jul;8(2):110-115. doi: 10.7774/cevr.2019.8.2.110. Epub 2019 Jul 31.
6
The hyperferremic mouse model for the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates.
Arch Med Res. 1997 Spring;28(1):41-5.
7
Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.
J Infect. 2024 Sep;89(3):106225. doi: 10.1016/j.jinf.2024.106225. Epub 2024 Jul 8.
8
A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.
Hum Vaccin Immunother. 2017 Nov 2;13(11):2548-2560. doi: 10.1080/21645515.2017.1356961. Epub 2017 Oct 30.
9
Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
Vaccine. 2004 Jun 30;22(20):2617-25. doi: 10.1016/j.vaccine.2003.12.009.
10
Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
Proteomics. 2006 Jun;6(11):3389-99. doi: 10.1002/pmic.200500502.
引用本文的文献
1
A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.
NPJ Vaccines. 2025 Jul 5;10(1):146. doi: 10.1038/s41541-025-01190-1.
2
Isolation of Extracellular Outer Membrane Vesicles (OMVs) from Using EVscore47 Beads.
Molecules. 2024 Apr 17;29(8):1831. doi: 10.3390/molecules29081831.
3
Evaluating vaccine-elicited antibody activities against : cross-protective responses elicited by the 4CMenB meningococcal vaccine.
Infect Immun. 2023 Dec 12;91(12):e0030923. doi: 10.1128/iai.00309-23. Epub 2023 Nov 22.
4
Immune responses to and implications for vaccine development.
Front Immunol. 2023 Aug 17;14:1248613. doi: 10.3389/fimmu.2023.1248613. eCollection 2023.
5
Preventing invasive meningococcal disease in early infancy.
Hum Vaccin Immunother. 2022 Nov 30;18(5):1979846. doi: 10.1080/21645515.2021.1979846. Epub 2022 Apr 28.
6
Recent Progress Towards a Gonococcal Vaccine.
Front Cell Infect Microbiol. 2022 Apr 11;12:881392. doi: 10.3389/fcimb.2022.881392. eCollection 2022.
7
An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study Protocol.
Vaccines (Basel). 2022 Feb 16;10(2):309. doi: 10.3390/vaccines10020309.
8
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Vaccine. 2022 Mar 18;40(13):2068-2075. doi: 10.1016/j.vaccine.2022.02.029. Epub 2022 Feb 8.
9
Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea.
Vaccines (Basel). 2021 Jul 20;9(7):804. doi: 10.3390/vaccines9070804.
10
Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.
Hum Vaccin Immunother. 2021 May 4;17(5):1450-1454. doi: 10.1080/21645515.2020.1827614. Epub 2021 Jan 11.
本文引用的文献
1
Impact of meningococcal group B OMV vaccines, beyond their brief.
Hum Vaccin Immunother. 2018 May 4;14(5):1058-1063. doi: 10.1080/21645515.2017.1381810. Epub 2017 Nov 17.
2
Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14.
3
A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
Vaccine. 2017 Jan 11;35(3):427-434. doi: 10.1016/j.vaccine.2016.11.071. Epub 2016 Nov 29.
4
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
N Engl J Med. 2016 Jul 21;375(3):220-8. doi: 10.1056/NEJMoa1514866.
5
Meningococcal B vaccine and the vision of a meningitis free world.
J Prev Med Hyg. 2015 Aug 31;56(3):E140-3.
6
Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines.
Vaccine. 2015 Jul 17;33(31):3628-35. doi: 10.1016/j.vaccine.2015.06.046. Epub 2015 Jun 17.
7
Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.
Vaccine. 2014 Mar 5;32(11):1280-6. doi: 10.1016/j.vaccine.2013.12.070. Epub 2014 Jan 30.
8
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.
Microbiol Mol Biol Rev. 2013 Jun;77(2):234-52. doi: 10.1128/MMBR.00056-12.
9
[Effectiveness of the anti-meningococcal vaccine VA-MENGO-BC in the first year of life of Cuban children, 1997-2008].
Rev Cubana Med Trop. 2011 May-Aug;63(2):155-60.
10
[Characterization of Neisseria meningitidis strains isolated from carriers in Cuba during 20 years].
Rev Cubana Med Trop. 2006 May-Aug;58(2):124-33.
Zotero 插件